4//SEC Filing
DANIELS RONALD J 4
Accession 0000899243-21-050130
CIK 0001743881other
Filed
Dec 29, 7:00 PM ET
Accepted
Dec 30, 8:17 PM ET
Size
8.7 KB
Accession
0000899243-21-050130
Insider Transaction Report
Form 4
DANIELS RONALD J
Director
Transactions
- Sale
Common Stock
2021-12-28$12.80/sh−11,745$150,336→ 0 total - Purchase
Common Stock
2021-12-28$12.73/sh+11,745$149,514→ 11,745 total - Purchase
Common Stock
2021-12-30$14.34/sh+10,402$149,165→ 10,402 total
Footnotes (3)
- [F1]The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions.
- [F2]Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3.
- [F3]Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
IncorporatedOntario, Canada
Related Parties
1- filerCIK 0001164475
Filing Metadata
- Form type
- 4
- Filed
- Dec 29, 7:00 PM ET
- Accepted
- Dec 30, 8:17 PM ET
- Size
- 8.7 KB